

Company background



Abylnx focuses on discovering and developing nanobodies, a novel class of protein based drug candidates. The company has alliances with a number of global pharmaceutical companies.



AMT develops gene-based therapies for orphan diseases.



Arpida focuses on the discovery and development of antibiotics for the treatment of severe bacterial infections.



Arseus is the former professional health division of Omega Pharma that recently went public. Arseus distributes and resells dental equipment, medical equipment, pharmaceuticals, and provides integrated IT solutions for healthcare professionals.



Crucell focuses on the development, production and marketing of vaccines and antibodies against infectious disease worldwide.



Devgen is an integrated agribusiness focusing on the development and commercialisation of biotech and chemical solutions for crop protection.



Fornix is focused on the development and sale of diagnostic and therapeutic allergen products, the distribution of medical aids and nursing disposables.



Galapagos is a drug discovery company that is developing small molecule drugs for bone and joint diseases based on proprietary targets. Through its services division BioFocus DPI, it is offering a broad spectrum of drug discovery services.



Intercell develops vaccines for the prevention and treatment of infectious diseases.



MorphoSys develops fully human antibodies, which are tailored to treat specific diseases and can also be used for research and diagnostics purposes.



OctoPlus focuses on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. The products are based on proprietary drug delivery technologies.



Omega Pharma is a prominent OTC intermediary for pharmacists throughout Europe and is acting as a main consolidator in the fragmented European OTC market.



OncoMethylome develops innovative and improved diagnostic and personalised treatment tests for the oncology market.



Pharming develops protein therapeutics for unmet medical needs. The company's products include potential treatments for genetic disorders and specialty products for surgical indications.



ThromboGenics develops products in the field of vascular and eye diseases.

